NEWS

Blog » Low Rates of Tobacco Dependence Treatment in Patients Hospitalized with Substance Use Disorders

Low Rates of Tobacco Dependence Treatment in Patients Hospitalized with Substance Use Disorders

Created Jun 21 2019, 12:14 PM by Wolters Kluwer Health
  • Journal of Addiction Medicine

June 21, 2019 – Tobacco dependence is very common in patients hospitalized with substance use disorders (SUDs) – but most don't receive recommended treatment for tobacco dependence while in the hospital, reports a study in the Journal of Addiction Medicine, the official journal of the American Society of Addiction Medicine (ASAM). The journal is published in the Lippincott portfolio by Wolters Kluwer.

"Inpatient addiction consultations represent a missed opportunity to counsel patients with SUDs to quit smoking," according to the new research by Hasmeena Kathuria, MD, of Boston University School of Medicine and colleagues. Their report includes suggestions from both patients and physicians on tobacco treatment strategies for this vulnerable group of patients.

Targeting Smoking in Inpatient Care for SUDs

The researchers analyzed records from nearly 700 patients with SUDs admitted to the Addiction Consult Service (ACS) at a large safety-net hospital. For most patients, SUD included heroin, often along with cocaine and/or alcohol.

Records were reviewed to identify whether the patients received treatment for tobacco dependence. The analysis focused on the recommended "5 A's"of tobacco treatment: Ask about tobacco use, Advise smokers to quit, Assess whether the person is willing to try quitting, Assist them in their attempt, and Arrange follow-up care.

Most patients with SUD were asked about tobacco use, and 75.5 percent were smokers. By comparison, about 18 percent of patients without SUD at the same hospital were current smokers.

However, only a minority of patients with SUD who smoked received any of the other recommended treatment steps. About 22 percent received "assistance" treatment steps – most often consisting of nicotine patches, intended to ease nicotine withdrawal symptoms during the hospital stay. "Only 5.4 percent of hospitalized SUD smokers received the full 5 A's approach from the ACS team," Dr. Kathuria and colleagues write.

Why wasn't tobacco dependence addressed more often? Physicians said that they typically discuss tobacco treatment in the outpatient clinic, but several patients said that they don't make outpatient visits. "Many patients would welcome discussions on tobacco dependence while hospitalized," the researchers write.

The addiction medicine physicians identified several barriers to tobacco treatment in the hospital. The doctors perceived that treating tobacco dependence in the hospital "is not a priority" for SUD patients, who would find it difficult to "quit all substances at once."

The ACS physicians also identified some factors that facilitated treatment, including linking smoking-cessation efforts to the success of SUD treatment. One physician suggested the message: "If you're able to quit smoking, it's a very positive prognostic sign for you to be able to do well on the rest of your addiction treatment."

Based on discussions with both patients and physicians, the authors outline a framework for in-hospital and follow-up treatment for tobacco dependence in SUD patients. Initial treatment can include nicotine replacement therapy or other pharmacotherapy such as varenicline to manage symptoms of tobacco withdrawal.

Smoking cessation counseling should be discussed in the hospital when the patient is stable from acute drug or alcohol withdrawal, and tobacco treatment should be continued during follow up treatment for SUD in the office and/or addiction treatment centers. Dr. Kathuria and colleagues add that to reduce disparities in smoking cessation outcomes in SUD patients, "System-level changes are needed to coordinate treatment of tobacco and other drug dependence in hospitalized smokers."

Click here to read "Patient and Physician Perspectives on Treating Tobacco Dependence in Hospitalized Smokers With Substance Use Disorders"

DOI: 10.1097/ADM.0000000000000503

###

About Journal of Addiction Medicine

The mission of Journal of Addiction Medicine, the official journal of the American Society of Addiction Medicine, is to promote excellence in the practice of addiction medicine and in clinical research as well as to support Addiction Medicine as a mainstream medical specialty. Published six times a year, the Journal is designed for all physicians and other mental health professionals who need to keep up-to-date with the treatment of addiction. Under the guidance of an esteemed Editorial Board, peer-reviewed articles published in the Journal focus on developments in addiction medicine as well as on treatment innovations and ethical, economic, forensic, and social topics. Visit us on the web at www.JournalAddictionMedicine.com .

About The American Society of Addiction Medicine

The American Society of Addiction Medicine (ASAM) is a professional society representing more than 6000 physicians, clinicians, and associated professionals in the field of addiction medicine. ASAM is dedicated to increasing access and improving the quality of addiction treatment, educating physicians and the public, supporting research and prevention, and promoting the appropriate role of physicians in the care of patients with addiction. Visit us on the web at www.ASAM.org; follow @ASAMorg on Twitter.

About Wolters Kluwer

Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.

Wolters Kluwer reported 2018 annual revenues of €4.3 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 18,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students with advanced clinical decision support, learning and research and clinical intelligence. For more information about our solutions, visit http://healthclarity.wolterskluwer.com and follow us on LinkedIn and Twitter @WKHealth.

For more information, visit www.wolterskluwer.com, follow us on TwitterFacebookLinkedIn, and YouTube.

Media Contacts

Connie Hughes

Director, Corporate Communications, Health Learning, Research & Practice

+1 646-674-6348​

Email

Loading